Skip to main content
Top
Published in: Journal of Cancer Research and Clinical Oncology 4/2010

01-04-2010 | Original Paper

Age as a prognostic factor for patients with osteosarcoma: an analysis of 438 patients

Authors: Matthew T. Harting, Kevin P. Lally, Richard J. Andrassy, Ara A. Vaporciyan, Charles S. Cox Jr., Andrea Hayes-Jordan, Martin L. Blakely

Published in: Journal of Cancer Research and Clinical Oncology | Issue 4/2010

Login to get access

Abstract

Background

It is unclear whether age at diagnosis is an important prognostic factor in patients with osteosarcoma. Understanding this relationship could yield valuable insight into therapeutic rationale, focus patient selection for clinical trials, advance molecular concepts and theories, and expand current principles guiding prognosis. Our aim was to understand if age at diagnosis is a prognostic indicator for eventual outcome, as measured by disease-free survival and overall survival in patients with osteosarcoma.

Methods

Our cohort consisted of 438 patients of all ages who were diagnosed with osteosarcoma between 1 January 1980 and 31 December 2000 and who underwent the majority of their treatment at M.D. Anderson Cancer Center (MDACC). Patient and tumor specific variables were collected including patient demographics, patient history, primary tumor information (i.e., location, size, histology, extension, necrosis, etc.), treatment strategy (i.e., surgery, chemotherapy, and/or radiotherapy), metastatic disease information, long-term follow-up, and eventual outcome. Statistical analyses, including univariate and multivariate analyses were performed, with overall survival and disease-free survival as the primary outcome measures.

Results

The median age at diagnosis was 18.1 years (range 2 months to 78.8 years). Median follow-up was 4.2 years (range 5 days to 22.8 years) for all patients and 12.3 years (range 1 month to 22.8 years) for 209 surviving patients. Survival rates at 5, 10, and 15 years were 54.1, 47.2, and 45.2%, respectively. On univariate analyses, age ≥ 40 was found to be a poor prognostic factor. Other prognostic factors included tumor size, metastasis at diagnosis, soft-tissue tumor extension, surgery type, chemotherapy group, and tumor necrosis. Age was not identified a statistically significant prognostic variable on multivariate analysis.

Conclusions

Age at diagnosis does not appear to be a significant independent prognostic variable for overall survival or disease-free survival in patients with osteosarcoma. Although our data indicate that patients in the fifth decade and older fare worse than younger patients, other variables such as tumor necrosis, tumor extension, and tumor location are likely responsible for the observed decline in overall survival and disease-free survival.
Footnotes
1
There is no graphical evidence or substantive reason to believe that the effects of any covariate are non-proportional over time.
 
Literature
go back to reference Alessandri AJ, Goddard KJ, Blair GK et al (2000) Age is the major determinant of recurrence in pediatric differentiated thyroid carcinoma. Med Pediatr Oncol 35:41–46CrossRefPubMed Alessandri AJ, Goddard KJ, Blair GK et al (2000) Age is the major determinant of recurrence in pediatric differentiated thyroid carcinoma. Med Pediatr Oncol 35:41–46CrossRefPubMed
go back to reference Bentzen SM, Poulsen HS, Kaae S et al (1988) Prognostic factors in osteosarcomas. A regression analysis. Cancer 62:194–202CrossRefPubMed Bentzen SM, Poulsen HS, Kaae S et al (1988) Prognostic factors in osteosarcomas. A regression analysis. Cancer 62:194–202CrossRefPubMed
go back to reference Bielack SS, Kempf-Bielack B, Delling G et al (2002) Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 20:776–790CrossRefPubMed Bielack SS, Kempf-Bielack B, Delling G et al (2002) Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 20:776–790CrossRefPubMed
go back to reference Ferrari S, Bertoni F, Mercuri M et al (2001) Predictive factors of disease-free survival for non-metastatic osteosarcoma of the extremity: an analysis of 300 patients treated at the Rizzoli Institute. Ann Oncol 12:1145–1150CrossRefPubMed Ferrari S, Bertoni F, Mercuri M et al (2001) Predictive factors of disease-free survival for non-metastatic osteosarcoma of the extremity: an analysis of 300 patients treated at the Rizzoli Institute. Ann Oncol 12:1145–1150CrossRefPubMed
go back to reference French Bone Tumor Study Group (1988) Age and dose of chemotherapy as major prognostic factors in a trial of adjuvant therapy of osteosarcoma combining two alternating drug combinations and early prophylactic lung irradiation. Cancer 61:1304–1311CrossRef French Bone Tumor Study Group (1988) Age and dose of chemotherapy as major prognostic factors in a trial of adjuvant therapy of osteosarcoma combining two alternating drug combinations and early prophylactic lung irradiation. Cancer 61:1304–1311CrossRef
go back to reference Glasser DB, Lane JM, Huvos AG et al (1992) Survival, prognosis, and therapeutic response in osteogenic sarcoma. The Memorial Hospital experience. Cancer 69:698–708CrossRefPubMed Glasser DB, Lane JM, Huvos AG et al (1992) Survival, prognosis, and therapeutic response in osteogenic sarcoma. The Memorial Hospital experience. Cancer 69:698–708CrossRefPubMed
go back to reference Grimer RJ, Cannon SR, Taminiau AM et al (2003) Osteosarcoma over the age of forty. Eur J Cancer 39:157–163CrossRefPubMed Grimer RJ, Cannon SR, Taminiau AM et al (2003) Osteosarcoma over the age of forty. Eur J Cancer 39:157–163CrossRefPubMed
go back to reference Hudson M, Jaffe MR, Jaffe N et al (1990) Pediatric osteosarcoma: therapeutic strategies, results, and prognostic factors derived from a 10-year experience. J Clin Oncol 8:1988–1997PubMed Hudson M, Jaffe MR, Jaffe N et al (1990) Pediatric osteosarcoma: therapeutic strategies, results, and prognostic factors derived from a 10-year experience. J Clin Oncol 8:1988–1997PubMed
go back to reference Joshi D, Anderson JR, Paidas C et al (2004) Age is an independent prognostic factor in Rhabdomyosarcoma: a report from the soft tissue sarcoma committee on the children’s oncology group. Pediatr Blood Cancer 42:64–73CrossRefPubMed Joshi D, Anderson JR, Paidas C et al (2004) Age is an independent prognostic factor in Rhabdomyosarcoma: a report from the soft tissue sarcoma committee on the children’s oncology group. Pediatr Blood Cancer 42:64–73CrossRefPubMed
go back to reference Kager L, Zoubek A, Potschger U et al (2003) Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 21:2011–2018CrossRefPubMed Kager L, Zoubek A, Potschger U et al (2003) Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 21:2011–2018CrossRefPubMed
go back to reference Lockshin MD, Higgins IT (1968) Prognosis in osteogenic sarcoma. Clin Orthop 58:85–101PubMed Lockshin MD, Higgins IT (1968) Prognosis in osteogenic sarcoma. Clin Orthop 58:85–101PubMed
go back to reference Meyers PA, Heller G, Healey J et al (1992) Chemotherapy for non-metastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol 10:5–15PubMed Meyers PA, Heller G, Healey J et al (1992) Chemotherapy for non-metastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol 10:5–15PubMed
go back to reference Moriguchi S, Maehara Y, Korenaga D et al (1993) Relationship between age and the time of surgery and prognosis after gastrectomy for gastric cancer. J Surg Oncol 52:119–123CrossRefPubMed Moriguchi S, Maehara Y, Korenaga D et al (1993) Relationship between age and the time of surgery and prognosis after gastrectomy for gastric cancer. J Surg Oncol 52:119–123CrossRefPubMed
go back to reference Nixon AJ, Neuberg D, Hayes DF et al (1994) Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer. J Clin Oncol 12:888–894PubMed Nixon AJ, Neuberg D, Hayes DF et al (1994) Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer. J Clin Oncol 12:888–894PubMed
go back to reference Paksoy M, Ipek T, Colak T et al (1999) Influence of age on prognosis and management of patients with colorectal carcinoma. Eur J Surg 165:55–59CrossRefPubMed Paksoy M, Ipek T, Colak T et al (1999) Influence of age on prognosis and management of patients with colorectal carcinoma. Eur J Surg 165:55–59CrossRefPubMed
go back to reference Petrilli AS, Gentil FC, Epelman S et al (1991) Increased survival, limb preservation, and prognostic factors for osteosarcoma. Cancer 68:733–737CrossRefPubMed Petrilli AS, Gentil FC, Epelman S et al (1991) Increased survival, limb preservation, and prognostic factors for osteosarcoma. Cancer 68:733–737CrossRefPubMed
go back to reference Raymond AK, Chawla SP, Carrasco CH (1987) Osteosarcoma chemotherapy effect: a prognostic factor. Semin Diagn Pathol 4:212–236PubMed Raymond AK, Chawla SP, Carrasco CH (1987) Osteosarcoma chemotherapy effect: a prognostic factor. Semin Diagn Pathol 4:212–236PubMed
go back to reference Rytting M, Pearson P, Raymond KA et al (2000) Osteosarcoma in preadolescent patients. Clin Orthop 373:39–50CrossRefPubMed Rytting M, Pearson P, Raymond KA et al (2000) Osteosarcoma in preadolescent patients. Clin Orthop 373:39–50CrossRefPubMed
go back to reference Scranton PE, DeCicco FA, Totten RS et al (1975) Prognostic factors in osteosarcoma. A review of 20 years’ experience at the University of Pittsburg Health Center Hospitals. Cancer 36:2179–2191PubMed Scranton PE, DeCicco FA, Totten RS et al (1975) Prognostic factors in osteosarcoma. A review of 20 years’ experience at the University of Pittsburg Health Center Hospitals. Cancer 36:2179–2191PubMed
go back to reference Spanier SS, Shuster JJ, VanderGriend RA (1990) The effect of local extent of the tumor on prognosis in osteosarcoma. J Bone Joint Surg 72:643–654PubMed Spanier SS, Shuster JJ, VanderGriend RA (1990) The effect of local extent of the tumor on prognosis in osteosarcoma. J Bone Joint Surg 72:643–654PubMed
go back to reference Winkler K, Beron G, Kotz R et al (1984) Neoadjuvant chemotherapy for osteogenic sarcoma: results of a cooperative German/Austrian study. J Clin Oncol 2:617–624PubMed Winkler K, Beron G, Kotz R et al (1984) Neoadjuvant chemotherapy for osteogenic sarcoma: results of a cooperative German/Austrian study. J Clin Oncol 2:617–624PubMed
go back to reference Xiong Q, Valero V, Kau V et al (2001) Female patients with breast carcinoma age 30 years and younger have a poor prognosis. The M.D. Anderson Cancer Center experience. Cancer 92:2523–2528CrossRefPubMed Xiong Q, Valero V, Kau V et al (2001) Female patients with breast carcinoma age 30 years and younger have a poor prognosis. The M.D. Anderson Cancer Center experience. Cancer 92:2523–2528CrossRefPubMed
go back to reference Yusim I, Mermershtain W, Neulander E et al (2002) Influence of age on the prognosis of patients with renal cell carcinoma (RCC). Onkologie 25:548–550CrossRefPubMed Yusim I, Mermershtain W, Neulander E et al (2002) Influence of age on the prognosis of patients with renal cell carcinoma (RCC). Onkologie 25:548–550CrossRefPubMed
Metadata
Title
Age as a prognostic factor for patients with osteosarcoma: an analysis of 438 patients
Authors
Matthew T. Harting
Kevin P. Lally
Richard J. Andrassy
Ara A. Vaporciyan
Charles S. Cox Jr.
Andrea Hayes-Jordan
Martin L. Blakely
Publication date
01-04-2010
Publisher
Springer-Verlag
Published in
Journal of Cancer Research and Clinical Oncology / Issue 4/2010
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-009-0690-5

Other articles of this Issue 4/2010

Journal of Cancer Research and Clinical Oncology 4/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine